Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.38 |
| ▸ | ITGAL | P20701 | 4/20 | 0.38 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 3/20 | 0.35 |
| ▸ | TACR3 | P29371 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30085387 | 1.00 | METAP2 (0.39) | METAP2IDH2ITGB2ICAM1ITGAL | |
| SCHEMBL28895082 | 1.00 | METAP2 (0.39) | METAP2IDH2ITGB2ICAM1ITGAL | |
| SCHEMBL25458596 | 0.87 | NPC1 (0.38) | ITGB2ICAM1ITGAL | |
| SCHEMBL28894627 | 0.82 | ABL1 (0.47) | METAP2IDH2RAF1BRAFABL1 | |
| SCHEMBL30085487 | 0.82 | ABL1 (0.47) | METAP2IDH2RAF1BRAFABL1 | |
| SCHEMBL28894671 | 0.82 | CYP3A4 (0.48) | IDH2ABL1 | |
| SCHEMBL30085381 | 0.82 | CYP3A4 (0.48) | IDH2ABL1 | |
| SCHEMBL28894630 | 0.82 | ABL1 (0.47) | METAP2IDH2RAF1BRAFABL1 | |
| SCHEMBL28894669 | 0.82 | CYP3A4 (0.48) | IDH2ABL1 | |
| SCHEMBL25460557 | 0.81 | PIM1 (0.48) | P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115397818-A | Aminopyrimidine derivatives and their use as modulators of arene receptors | 东亚ST株式会社 | 2022-11-25 | — | — | CN | claimed |
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| CN-115397818-A | Aminopyrimidine derivatives and their use as modulators of arene receptors | 东亚ST株式会社 | 2022-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150970-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | METAP2 802/4885IDH2 1095/4885ITGB2 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.